vTv Therapeutics (NASDAQ:VTVT) Lowered to Sell Rating by Wall Street Zen

Posted by Francis Steltz on Aug 9th, 2026

Wall Street Zen downgraded shares of vTv Therapeutics (NASDAQ:VTVT – Free Report) from a buy rating to a sell rating in a report issued on Saturday morning.

Several other equities analysts also recently weighed in on the company. Weiss Ratings raised vTv Therapeutics from a “sell (d-)” rating to a “sell (d+)” rating in a research note on Monday, May 18th. HC Wainwright decreased their target price on vTv Therapeutics from $45.00 to $42.00 and set a “buy” rating on the stock in a research report on Thursday. Zacks Research lowered vTv Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, June 11th. BTIG Research raised their price target on vTv Therapeutics from $49.00 to $57.00 and gave the company a “buy” rating in a research report on Thursday, July 16th. Finally, Rodman & Renshaw assumed coverage on vTv Therapeutics in a research note on Tuesday, June 30th. They set a “buy” rating and a $67.00 price target for the company. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, vTv Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $55.83.

Check Out Our Latest Stock Report on VTVT

vTv Therapeutics Trading Up 2.2%

VTVT stock opened at $35.37 on Friday. The company’s 50-day moving average price is $33.40 and its 200 day moving average price is $34.80. vTv Therapeutics has a 52 week low of $14.00 and a 52 week high of $44.00. The company has a market cap of $139.32 million, a P/E ratio of -33.37 and a beta of 0.28.

vTv Therapeutics (NASDAQ:VTVT – Get Free Report) last issued its earnings results on Thursday, August 6th. The biotechnology company reported ($1.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.08). On average, equities research analysts expect that vTv Therapeutics will post -2.52 earnings per share for the current year.

Institutional Trading of vTv Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC raised its stake in vTv Therapeutics by 84.3% in the 4th quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company’s stock valued at $1,128,000 after purchasing an additional 12,896 shares during the last quarter. Goldman Sachs Group Inc. acquired a new stake in shares of vTv Therapeutics during the 4th quarter worth about $221,000. Finally, 683 Capital Management LLC acquired a new stake in shares of vTv Therapeutics during the 4th quarter worth about $731,000. Hedge funds and other institutional investors own 17.51% of the company’s stock.

Key vTv Therapeutics News

Here are the key news stories impacting vTv Therapeutics this week:

Positive Sentiment: HC Wainwright maintained its Buy rating and $42 price target for vTv Therapeutics, implying potential upside from recent trading levels. However, the firm’s revised estimates continue to project losses.
Neutral Sentiment: vTv Therapeutics reported its second-quarter 2026 financial results and provided a corporate update, giving investors additional information on the company’s financial position and development programs. vTv Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Negative Sentiment: HC Wainwright reduced its EPS forecasts across nearly all future periods. Its FY2026 outlook moved from a $0.02 profit to a $0.97 loss, while FY2027 EPS was cut from a $3.17 loss to a $4.60 loss. Forecasts were also lowered for Q3 and Q4 2026 and FY2028-FY2030, signaling expectations for larger or more prolonged losses.
Negative Sentiment: The company’s latest quarterly results included an EPS loss of $1.05, missing the consensus estimate for a $0.97 loss. Analysts expect vTv Therapeutics to remain unprofitable, with consensus current-year EPS of approximately negative $2.19.
Negative Sentiment: Wall Street Zen downgraded VTVT to Sell, adding pressure to the investment case and contrasting with HC Wainwright’s Buy rating. vTv Therapeutics Downgraded by Wall Street Zen to Sell

vTv Therapeutics Company Profile

(Get Free Report)

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.